127 related articles for article (PubMed ID: 35019815)
1. Predicting biomarkers in intact older adults and those with amnestic Mild Cognitive Impairment, and mild Alzheimer's Disease using the Repeatable Battery for the Assessment of Neuropsychological Status.
Suhrie KR; Hammers DB; Porter SM; Dixon AM; King JB; Anderson JS; Duff K; Hoffman JM
J Clin Exp Neuropsychol; 2021 Nov; 43(9):861-878. PubMed ID: 35019815
[TBL] [Abstract][Full Text] [Related]
2. Repeatable battery for the assessment of neuropsychological status and its relationship to biomarkers of Alzheimer's disease.
Duff K; Suhrie KR; Hammers DB; Dixon AM; King JB; Koppelmans V; Hoffman JM
Clin Neuropsychol; 2023 Jan; 37(1):157-173. PubMed ID: 34713772
[TBL] [Abstract][Full Text] [Related]
3. Relationship between
Hammers DB; Atkinson TJ; Dalley BC; Suhrie KR; Beardmore BE; Burrell LD; Horn KP; Rasmussen KM; Foster NL; Duff K; Hoffman JM
Clin Neuropsychol; 2017 Apr; 31(3):531-543. PubMed ID: 28077020
[TBL] [Abstract][Full Text] [Related]
4. Change on the Repeatable Battery for the Assessment of Neuropsychological Status and its relationship to brain amyloid.
Duff K; Dixon AM; Embree L; Hoffman JM
J Clin Exp Neuropsychol; 2023 Mar; 45(2):105-117. PubMed ID: 37224404
[TBL] [Abstract][Full Text] [Related]
5. Recall and recognition subtests of the repeatable battery for the assessment of neuropsychological status and their relationship to biomarkers of Alzheimer's disease.
Euler MJ; Duff K; King JB; Hoffman JM
Neuropsychol Dev Cogn B Aging Neuropsychol Cogn; 2023; 30(6):885-902. PubMed ID: 36110031
[TBL] [Abstract][Full Text] [Related]
6. Relationship between a novel learning slope metric and Alzheimer's disease biomarkers.
Hammers DB; Suhrie K; Dixon A; Gradwohl BD; Archibald ZG; King JB; Spencer RJ; Duff K; Hoffman JM
Neuropsychol Dev Cogn B Aging Neuropsychol Cogn; 2022 Sep; 29(5):799-819. PubMed ID: 33952156
[TBL] [Abstract][Full Text] [Related]
7. Recognition subtests for the Repeatable Battery for the Assessment of Neuropsychological Status: Preliminary data in cognitively intact older adults, amnestic Mild Cognitive Impairment, and Alzheimer's disease.
Duff K; Suhrie KR; Dalley BCA; Porter SM; Dixon AM
Clin Neuropsychol; 2021 Nov; 35(8):1415-1425. PubMed ID: 32883179
[No Abstract] [Full Text] [Related]
8. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Utility in detection and characterization of mild cognitive impairment due to Alzheimer's disease.
Karantzoulis S; Novitski J; Gold M; Randolph C
Arch Clin Neuropsychol; 2013 Dec; 28(8):837-44. PubMed ID: 23867976
[TBL] [Abstract][Full Text] [Related]
9. The Quick Dementia Rating System and Its Relationship to Biomarkers of Alzheimer's Disease and Neuropsychological Performance.
Duff K; Wan L; Levine DA; Giordani B; Fowler NR; Fagerlin A; King JB; Hoffman JM
Dement Geriatr Cogn Disord; 2022; 51(3):214-220. PubMed ID: 35477163
[TBL] [Abstract][Full Text] [Related]
10. The Use of Episodic Memory Tests for Screening in Clinical Trials for Early Alzheimer's Disease: A Comparison of the Free and Cued Selective Reminding Test (FCSRT) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
Teng E; Manser PT; Shah M; Pickthorn K; Hu N; Djakovic S; Swendsen H; Blendstrup M; Faccin G; Ostrowitzki S; Sink KM
J Prev Alzheimers Dis; 2023; 10(1):41-49. PubMed ID: 36641609
[TBL] [Abstract][Full Text] [Related]
11. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial.
Papp KV; Rofael H; Veroff AE; Donohue MC; Wang S; Randolph C; Grober E; Brashear HR; Novak G; Ernstrom K; Raman R; Aisen PS; Sperling R; Romano G; Henley D
J Prev Alzheimers Dis; 2022; 9(2):255-261. PubMed ID: 35542998
[TBL] [Abstract][Full Text] [Related]
13. RBANS memory percentage retention: No evidence of incremental validity beyond RBANS scores for diagnostic classification of mild cognitive impairment and dementia and for prediction of daily function.
Jodouin KA; O'Connell ME; Morgan DG
Appl Neuropsychol Adult; 2017; 24(5):420-428. PubMed ID: 27282346
[TBL] [Abstract][Full Text] [Related]
14. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
15. Sex modulates the ApoE ε4 effect on brain tau deposition measured by
Liu M; Paranjpe MD; Zhou X; Duy PQ; Goyal MS; Benzinger TLS; Lu J; Wang R; Zhou Y
Theranostics; 2019; 9(17):4959-4970. PubMed ID: 31410194
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
[TBL] [Abstract][Full Text] [Related]
17. Effect of APOE ε4 genotype on amyloid-β, glucose metabolism, and gray matter volume in cognitively normal individuals and amnestic mild cognitive impairment.
Li W; Li R; Yan S; Zhao Z; Shan Y; Qi Z; Lu J;
Eur J Neurol; 2023 Mar; 30(3):587-596. PubMed ID: 36448771
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
19. The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
Löwe LC; Gaser C; Franke K;
PLoS One; 2016; 11(7):e0157514. PubMed ID: 27410431
[TBL] [Abstract][Full Text] [Related]
20. Differential Effects of the Interaction Between the Education and APOE ε4 Allele on Amyloid-beta Retention and Memory Performances in Cognitively Normal Older Adults and Alzheimer's Disease Patients.
Kang DW; Wang SM; Na HR; Lee CU; Baek IH; Lim HK
Curr Alzheimer Res; 2020; 17(11):1023-1032. PubMed ID: 33372875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
